A subgroup analysis in which the sequence of EGFR-TKI treatment was stratified showed a significantly better mOS in patients with BIM-expression-negative NSCLC (20.7 vs. 28.9 months, P=0.04). This evidence concerns the gene EGFR and non-small cell lung carcinoma.